Navigation Links
TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade

ST. LOUIS, Nov. 24 /PRNewswire/ -- A study released recently in the British Journal of Urology detailed the results from biopsies of 140 men who received care at Washington University in St. Louis, Duke University, and the University of Michigan. The study, titled "Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer," found that TargetScan(R) template guided biopsy technology potentially produces a higher cancer detection rate and more accurate assessment of grade.

The TargetScan system combines 3-D image acquisition with a stationary probe, which helps physicians plan and execute targeted prostate biopsies through accurate needle placement within a template, which in turn, can provide confidence in identifying locations of significant cancer in the prostate.

"As physicians we are challenged to provide accurate diagnosis and define the true extent of the disease so we don't over or underestimate the significance of the cancer," said Dr. Gerald Andriole, Professor and Chief of Urology at Washington University in St Louis School of Medicine, a member of the multi-center team that conducted the evaluation of TargetScan. The study's lead author, Dr. Adam Kibel, also from Washington University, agrees. "This technology allows physicians to accurately biopsy the prostate since the location of each biopsy is calculated on the basis of the prostate's size and shape. This may allow us to more accurately find and define the disease. This may allow better monitoring of patients on active surveillance. Importantly, since the location of each biopsy site is recorded, re-biopsy or treatments can be performed with more precision."

TargetScan Touch(TM) is the most current system based on the TargetScan technology platform. TargetScan Touch was unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology annual meeting, and has been tested at several of the nation's leading medical centers.

TargetScan technology is developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University in St. Louis. "Traditional hand-manipulated devices allow the prostate gland to shift, which impedes accurate biopsy and placement accuracy. By stabilizing the prostate, physicians can now detect cancer with greater confidence," said Robert Mills, president, Envisioneering Medical Technologies.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit

KM-0022 A

SOURCE Envisioneering Medical Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses
2. Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures
3. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. VA Announces Expansion of Disability Evaluation System Pilot
6. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
7. Study sees need for standardized evaluation of antibody response to HIV-1
8. Hooper Holmes Announces Sale of Claims Evaluation Division
9. Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients
10. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
11. Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: